Pharmaceutical company Impax Laboratories Inc (NASDAQ:IPXL) reported on Tuesday the availability of the authorised generic version of Solodyn (minocycline HCl) extended-release tablets in 65 mg and 115 mg.
For the 12 months ending December 2017, Minocycline HCl extended-release tablets, 65 mg and 115 mg, had annual US sales of about USD148m according to IQVIA,
SOLODYN is indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older, added the company.
Impax is a specialty pharmaceutical company that markets its generic products through its Impax Generics division and its branded products through the Impax Specialty Pharma division.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream